[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-401277-105":59,"doc-detail-401277-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","prep-to-prevent-hiv-and-promote-sexual-health-updates-authorship-and-related-guidelines-highlights-of-changes-in-the-may-20-2022-edition","PrEP to Prevent HIV and Promote Sexual Health - Updates, Authorship, and Related Guidelines - Highlights of changes in the May 20, 2022 edition","","Provides updates, authorship information, and guideline highlights for “PrEP to Prevent HIV and Promote Sexual Health,” current as of May 20, 2022. Incorporates new data since the prior August 2021 edition and adds recommendations for long-acting injectable PrEP using cabotegravir, an integrase strand transfer inhibitor. Identifies intended users as New York State clinicians recommending, initiating, or maintaining PrEP care, and summarizes key clinical sections including access, eligibility, contraindications, regimen selection, protection timing, monitoring, and laboratory testing.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prep-to-prevent-hiv-and-promote-sexual-health-updates-authorship-and-related-guidelines-highlights-of-changes-in-the-may-20-2022-edition/401277/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prep-to-prevent-hiv-and-promote-sexual-health-updates-authorship-and-related-guidelines-highlights-of-changes-in-the-may-20-2022-edition/401277.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-27",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What changes were made in the May 20, 2022 edition of the guideline?","Question",{"text":113,"@type":114},"Updates incorporate data new since the August 2021 edition and include recommendations for long-acting injectable cabotegravir as PrEP.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Who is the intended audience for this PrEP guideline?",{"text":118,"@type":114},"New York State clinicians who recommend, initiate, or maintain PrEP care for individuals at risk of acquiring HIV.",{"name":120,"@type":111,"acceptedAnswer":121},"Which major topics does the guideline cover for PrEP implementation?",{"text":122,"@type":114},"It includes access and coverage, eligibility (including candidates and adolescents), counseling and assessment before initiation, contraindications and PrEP failure, regimen selection and comparisons, time to protection, engagement in care, adherence, pregnancy considerations, and laboratory testing including HIV testing.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},401277,1790526588,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","PrEP to Prevent HIV and Promote Sexual Health  \nUpdates, Authorship, and Related Guidelines  \nDate of current publication  \nHighlights of changes, additions, and updates in the May 20, 2022 edition  \nIntended users  \nLead author Writing group  \nAuthor and writing group conflict of interest disclosures  \nDate of original publication Committee  \nDeveloper and funder Development process Related NYSDOH AI guidelines  \nMay 20, 2022  \nUpdates were made to incorporate data that are new since the previous edition was published in Aug. 2021 and to include recommendations for the long-acting injectable formulation of the integrase strand transfer inhibitor cabotegravir as PrEP  \nNew York State clinicians who are recommending, initiating, or maintaining PrEP care for individuals at risk of acquiring HIV  \nRona M. Vail, MD  \nSteven M. Fine, MD, PhD; Joseph P. McGowan, MD, FACP, FIDSA; Samuel T. Merrick, MD; Asa Radix, MD, MPH, PhD; Jessica Rodrigues; Christopher J. Hoffmann, MD, MPH; Lyn C. Stevens, MS, NP, ACRN; Charles J. Gonzalez, MD  \nJoseph P. McGowan, MD, FACP, FIDSA: Institutional Pharma grant recipient/support, clinical trial; Gilead  \nOctober 10, 2019  \nMedical Care Criteria Committee  \nNew York State Department of Health AIDS Institute (NYSDOH AI) See Supplement: Guideline Development and Recommendation Ratings  \n• Diagnosis and Management of Acute HIV Infection  \n• Hepatitis C Virus Screening, Testing, and Diagnosis in Adults  \n• HIV Testing  \n•  Prevention and Management of Hepatitis B Virus Infection in Adults With HIV  \n•  PEP to Prevent HIV Infection  \n• Rapid ART Initiation  \n• Selecting an Initial ART Regimen  \n•  Substance Use Harm Reduction in Medical Care  \n•  Substance Use Screening, Risk Assessment, and Use Disorder Diagnosis in Adults  \nNYSDOH AI Guidance  \n•  Resource: ART Drug-Drug Interactions  \n•  GOALS Framework for Sexual History Taking in Primary Care  \n•  U=U Guidance for Implementation in Clinical Settings  \nPrEP to Prevent HIV and Promote Sexual Health  \nDate of current publication: May 20, 2022  \nLead author: Rona M. Vail, MD  \nWriting group: Steven M. Fine, MD, PhD; Joseph P. McGowan, MD, FACP, FIDSA; Samuel T. Merrick, MD; Asa Radix, MD, MPH, PhD; Jessica Rodrigues; Christopher J. Hoffmann, MD, MPH; Lyn C. Stevens, MS, NP, ACRN; Charles J. Gonzalez, MD Committee: Medical Care Criteria Committee  \nDate of original publication: October 10, 2019  \nContents  \nPurpose of This Guideline .......................................................................................................................................................... 3  \nGoals ....................................................................................................................................................................................... 3  \nPrEP Access and Coverage ...................................................................................................................................................... 3  \nPrEP for Individuals at Risk of Acquiring HIV.............................................................................................................................. 5  \nPrEP Candidates ...................................................................................................................................................................... 5  \nPrEP for Adolescents ............................................................................................................................................................... 8  \nAssessment and Counseling Before PrEP Initiation ................................................................................................................ 8  \nPrEP in Comprehensive HIV Prevention Planning ................................................................................................................. 10  \nContraindications to PrEP Use ..............................................................................................................","cbCaisIsSJd95eUe","https://ap.wps.com/l/cbCaisIsSJd95eUe","pdf",1284735,56,"English","# Purpose of This Guideline\n# Goals\n# PrEP Access and Coverage\n# PrEP for Individuals at Risk of Acquiring HIV\n## PrEP Candidates\n## PrEP for Adolescents\n# Assessment and Counseling Before PrEP Initiation\n# PrEP in Comprehensive HIV Prevention Planning\n# Contraindications to PrEP Use\n# PrEP Failure\n# Choosing and Prescribing a PrEP Regimen\n# Comparison of Available Regimens\n# Time to Protection\n# Engagement in Care\n# Adherence\n# PrEP During Pregnancy\n# Laboratory Testing Before PrEP Initiation\n# HIV Testing","[{\"question\":\"What changes were made in the May 20, 2022 edition of the guideline?\",\"answer\":\"Updates incorporate data new since the August 2021 edition and include recommendations for long-acting injectable cabotegravir as PrEP.\"},{\"question\":\"Who is the intended audience for this PrEP guideline?\",\"answer\":\"New York State clinicians who recommend, initiate, or maintain PrEP care for individuals at risk of acquiring HIV.\"},{\"question\":\"Which major topics does the guideline cover for PrEP implementation?\",\"answer\":\"It includes access and coverage, eligibility (including candidates and adolescents), counseling and assessment before initiation, contraindications and PrEP failure, regimen selection and comparisons, time to protection, engagement in care, adherence, pregnancy considerations, and laboratory testing including HIV testing.\"}]","PrEP to Prevent HIV and Promote Sexual Health - Updates, Authorship, and Related Guidelines - Highlights of changes in the May 20, 2022 edition | PDF",1790518363,141]